Financial reports
20-F
2023 FY
Annual report (foreign)
8 Apr 24
20-F/A
2022 FY
Annual report (foreign) (amended)
3 Jul 23
20-F
2022 FY
Annual report (foreign)
18 Apr 23
20-F/A
2021 FY
Annual report (foreign) (amended)
30 Jan 23
20-F
2021 FY
Annual report (foreign)
21 Apr 22
20-F/A
2020 FY
Annual report (foreign) (amended)
28 Oct 21
20-F/A
2020 FY
Annual report (foreign) (amended)
18 Mar 21
20-F
2020 FY
Annual report (foreign)
12 Mar 21
Current reports
6-K
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
22 Jul 24
6-K
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
11 Jul 24
6-K
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
1 Jul 24
6-K
All resolutions presented by the Company have been adopted
26 Jun 24
6-K
Current report (foreign)
20 Jun 24
6-K
Biophytis extends its contract with Atlas to secure financing for its business activities
20 Jun 24
6-K
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
14 Jun 24
6-K
Biophytis announces filing of an IND application
11 Jun 24
6-K
Current report (foreign)
7 Jun 24
6-K
Biophytis announces the design of its phase 2 OBA clinical study in obesity
14 May 24
Registration and prospectus
25-NSE
Exchange delisting
28 Jun 24
F-1
Registration statement (foreign)
4 Aug 23
424B5
Prospectus supplement for primary offering
20 Jul 23
F-3
Shelf registration (foreign)
21 Apr 23
424B4
Prospectus supplement with pricing info
11 Feb 21
F-1/A
Registration statement (foreign) (amended)
8 Feb 21
FWP
Free writing prospectus
8 Feb 21
8-A12B
Registration of securities on exchange
4 Feb 21
F-1/A
Registration statement (foreign) (amended)
4 Feb 21
FWP
Free writing prospectus
2 Feb 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
2 May 23
CORRESP
Correspondence with SEC
27 Apr 23
UPLOAD
Letter from SEC
27 Apr 23
EFFECT
Notice of effectiveness
10 Feb 21
CERT
Certification of approval for exchange listing
8 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
CORRESP
Correspondence with SEC
19 Jan 21
UPLOAD
Letter from SEC
5 Jan 21
UPLOAD
Letter from SEC
17 Dec 20